Agomab says STENOVA open-label extension data for Crohn’s drug ontunisertib to be presented at UEG Week 2026

• Agomab disclosed open-label extension results from its Phase 2a STENOVA study of ontunisertib in fibrostenosing Crohn’s disease.
• Data will be presented in an oral session at UEG Week 2026 in Barcelona on Oct. 20.
• Findings from extended dosing supported plans to start the global NOV-ERA Phase 2b trial in the coming months.
• The extension study focused on longer-term safety and drug exposure, with exploratory tracking of clinical events and disease progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081605PRIMZONEFULLFEED1001277027) on October 08, 2026, and is solely responsible for the information contained therein.